These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 37768850)

  • 1. Designing multicenter individually randomized group treatment trials.
    Tong G; Tong J; Li F
    Biom J; 2024 Jan; 66(1):e2200307. PubMed ID: 37768850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing individually randomized group treatment trials with repeated outcome measurements using generalized estimating equations.
    Wang X; Turner EL; Li F
    Stat Med; 2024 Jan; 43(2):358-378. PubMed ID: 38009329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of complex, partially nested clustering in a three-arm individually randomized group treatment trial: A case study with the wHOPE trial.
    Tong G; Seal KH; Becker WC; Li F; Dziura JD; Peduzzi PN; Esserman DA
    Clin Trials; 2022 Feb; 19(1):3-13. PubMed ID: 34693748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size considerations for assessing treatment effect heterogeneity in randomized trials with heterogeneous intracluster correlations and variances.
    Tong G; Taljaard M; Li F
    Stat Med; 2023 Aug; 42(19):3392-3412. PubMed ID: 37316956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appropriate statistical methods for analysing partially nested randomised controlled trials with continuous outcomes: a simulation study.
    Candlish J; Teare MD; Dimairo M; Flight L; Mandefield L; Walters SJ
    BMC Med Res Methodol; 2018 Oct; 18(1):105. PubMed ID: 30314463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing three-level cluster randomized trials to assess treatment effect heterogeneity.
    Li F; Chen X; Tian Z; Esserman D; Heagerty PJ; Wang R
    Biostatistics; 2023 Oct; 24(4):833-849. PubMed ID: 35861621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size requirements for testing treatment effect heterogeneity in cluster randomized trials with binary outcomes.
    Maleyeff L; Wang R; Haneuse S; Li F
    Stat Med; 2023 Nov; 42(27):5054-5083. PubMed ID: 37974475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accounting for expected attrition in the planning of cluster randomized trials for assessing treatment effect heterogeneity.
    Tong J; Li F; Harhay MO; Tong G
    BMC Med Res Methodol; 2023 Apr; 23(1):85. PubMed ID: 37024809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size calculation for treatment effects in randomized trials with fixed cluster sizes and heterogeneous intraclass correlations and variances.
    Candel MJ; van Breukelen GJ
    Stat Methods Med Res; 2015 Oct; 24(5):557-73. PubMed ID: 25519890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Planning stepped wedge cluster randomized trials to detect treatment effect heterogeneity.
    Li F; Chen X; Tian Z; Wang R; Heagerty PJ
    Stat Med; 2024 Feb; 43(5):890-911. PubMed ID: 38115805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Best (but oft forgotten) practices: Efficient sample sizes for commonly used trial designs.
    Candel MJJM; van Breukelen GJP
    Am J Clin Nutr; 2023 Jun; 117(6):1063-1085. PubMed ID: 37270287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A readily available improvement over method of moments for intra-cluster correlation estimation in the context of cluster randomized trials and fitting a GEE-type marginal model for binary outcomes.
    Westgate PM
    Clin Trials; 2019 Feb; 16(1):41-51. PubMed ID: 30295512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size recalculation in multicenter randomized controlled clinical trials based on noncomparative data.
    Harden M; Friede T
    Biom J; 2020 Sep; 62(5):1284-1299. PubMed ID: 32128868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size calculation for cluster randomization trials with a time-to-event endpoint.
    Li J; Jung SH
    Stat Med; 2020 Nov; 39(25):3608-3623. PubMed ID: 33463748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accounting for unequal cluster sizes in designing cluster randomized trials to detect treatment effect heterogeneity.
    Tong G; Esserman D; Li F
    Stat Med; 2022 Apr; 41(8):1376-1396. PubMed ID: 34923655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individually randomized group treatment trials: a critical appraisal of frequently used design and analytic approaches.
    Pals SL; Murray DM; Alfano CM; Shadish WR; Hannan PJ; Baker WL
    Am J Public Health; 2008 Aug; 98(8):1418-24. PubMed ID: 18556603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Power and sample size calculations for cluster randomized trials with binary outcomes when intracluster correlation coefficients vary by treatment arm.
    Kennedy-Shaffer L; Hughes MD
    Clin Trials; 2022 Feb; 19(1):42-51. PubMed ID: 34879711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of multicenter clinical trials with very low event rates.
    Kim J; Troxel AB; Halpern SD; Volpp KG; Kahan BC; Morris TP; Harhay MO
    Trials; 2020 Nov; 21(1):917. PubMed ID: 33168073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Power considerations for generalized estimating equations analyses of four-level cluster randomized trials.
    Wang X; Turner EL; Preisser JS; Li F
    Biom J; 2022 Apr; 64(4):663-680. PubMed ID: 34897793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.